Scl-70 Autoantibody ELISA
The Calbiotech Scl-70 ELISA Kit is intended for the detection of IgG antibody to Scl-70 in human serum or plasma.
Systemic autoimmune disease is characterized by the presence of circulating auto-antibodies directed to a wide variety of cellular antigens. Systemic lupus erythematosis (SLE), commonly referred to as Lupus is the best known of these diseases. Other possible connective tissue diseases include mixed connective tissue disease (MCTD), Sjogren syndrome, sclerodema, and polymyositis/dermatomyositis. The majority can be diagnosed by clinical presentation and their antibody profiles to the various antigens involved, which include dsDNA, SM, RNP, SSA, SSB Scl-70, Jo1 and Histones. Therefore, immunoassays for autoantibodies are useful for diagnostic and prognostic evaluations of autoimmune disease. Scl-70 IgG antibodies react with human topoisomerase I of 100 kd molecular weight as well as its 70 kd fragment. Scl-70 antibodies are present in 20-40% of diffuse scleroderma patients and in about 20% of patients with limited scleroderma. Scl-70 antibodies are sometimes reported in classical SLE without features of scleroderma, which may explain the unexpected co-existence of marker autoantibodies for SLE and scleroderma. Some patients with silica-associated systemic sclerosis (SSc) have Scl-70 antibodies.
Diluted patient serum is added to wells coated with purified antigen. IgG specific antibody, if present, binds to the antigen. All unbound materials are washed away and the enzyme conjugate is added to bind to the antibody-antigen complex, if present. Excess enzyme conjugate is washed off and substrate is added. The plate is incubated to allow the hydrolysis of the substrate by the enzyme. The intensity of the color generated is proportional to the amount of IgG specific antibody in the sample.
- Hildebrandt S, Weiner ES, Senecal J-L, Noell GS, Earnshaw WC, Rothfield NF. Autoantibodies to topoisomerase I (Scl-70): analysis by gel diffusion, immunoblot, and enzyme-linked immunosorbent assay. Clin Immunol Immunopathol 1990;57:399-410.
- Hildebrandt S, Weiner E, Senécal J, et al. The IgG, IgM, and IgA isotypes of antitopoisomerase I and anticentromere autoantibodies. Arthritis Rheum 1990;33:724-7.
- Steen VD, Powell DL, Medsger TA Jr. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988;31:196-203.
- Hildebrandt S, Jäckh G, Weber S, Peter H-H. A long-term longitudinal isotypic study of antitopoisomerase I autoantibodies. Rheumatol Int 1993;12:321-4.
- Briggs DC, Vaughan RW, Welsh KI, Myers A, DuBois RM, Black CM. Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis. Lancet 1991;338:661-2.
- Mukai M, Sagawa A, Atsumi T, et al. 3 cases of anti-Scl-70 (topoisomerase I) antibody associated with central nervous system lupus without renal disorder. J Rheumatol 1993;20:91594-7.
- Stojanov L, Satoh M, Dooley MA, Kuwana M, Jennette JC, Reeves WH. Autoantibodies to topoisomerase I in a patient with systemic lupus erythematosus without features of scleroderma. Lupus 1995;4:314-7.
- Juarez C, Vila JL, Gelpi C, et al. Characterization of the antigen reactive with anti-Scl-70 antibodies and its application in an enzyme-linked immunosorbent assay. Arthritis Rheum 1988;31:108-15.